Full-Time

LIMS Master Data Specialist 3

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

Compensation Overview

$100k - $125k/yr

Rensselaer, NY, USA

In Person

Relocation assistance is available.

Bachelor's, Associate's

Category
Biology & Biotech (1)
Required Skills
GMP
Version Control
Data Governance

Get referred to Curia

See people who can refer or advise you

Requirements
  • An Associate’s or Bachelor’s degree in Life Sciences, Engineering, or a related STEM field.
  • Two to five years of experience in a GMP-regulated pharmaceutical or life sciences laboratory environment.
  • Understanding of analytical testing and techniques.
Responsibilities
  • Create and revise master data elements in the LabVantage LIMS platform, including test methods, specifications, analytical procedures, sampling plans, product parameters, and instrument mapping.
  • Enforce data integrity standards, version control, and data accuracy across laboratory processes, ensuring compliance with global corporate policies and regulatory standards such as FDA 21 CFR Part 11, cGMP, and ISO 17025.
  • Partner with laboratory subject matter experts to gather business requirements and map existing workflows to system capabilities.
  • Partner with IT system administrators to develop, test, and implement new functionality.
  • Serve as the first line of support for end-user issues and troubleshoot master data anomalies.
  • Assist with data migration during system upgrades, support routine troubleshooting of data-related issues, and escalate technical problems to system administrators or the vendor as needed.
  • Own and update Master Data Standard Operating Procedures, data maps, and LIMS validation documentation.
  • Build and maintain test definitions, sampling plans, specifications, and stability protocols in LIMS in collaboration with quality control subject matter experts.
  • Work with IT, quality assurance, and quality control leadership to test system settings, user roles, and permissions.
  • Support internal and external regulatory audits and inspections by providing LIMS documentation and system access as required.
  • Execute validation test scripts associated with LIMS.
  • Work with quality control leadership to support ongoing LIMS improvements and upgrades.
Desired Qualifications
  • Experience with LIMS as an end user and/or participation in an LIMS implementation.
  • Experience with major LIMS platforms such as LabVantage, LabWare, or STARLIMS.
  • Exceptional analytical thinking, strong attention to detail, and excellent verbal and written communication skills to bridge technical and scientific teams.

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Curia expanded Glasgow sterile drug product capacity in March 2026.
  • Curia completed a $4 million sterile API upgrade in Valladolid in October 2025.
  • Curia won a 2025 CDMO Leadership Award in Global Biologics.

What critics are saying

  • Curia is closing Burlington in 2026 and cutting 81 jobs.
  • Curia is working on an out-of-court restructuring with private credit lenders.
  • Asset sales like Pace’s New Jersey lab purchase signal continued portfolio shrinkage.

What makes Curia unique

  • Curia spans discovery through commercial manufacturing across small molecules and biologics.
  • Curia manufactures mRNA and self-replicating RNA, including Replicate Bioscience’s RBI-4000.
  • Curia runs 20+ global sites with sterile fill-finish and cell-line development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.